- Many ways to get 2X increased response from the same dose
this study does not appear to have tried any of the ways - such as use of co-factors like Magnesium, Vitamin K2, etc.
- This study does not seem to consider use of loading /bolus/Stoss doses, only maintenance doses
- No vitamin D test needed before supplementing (typically) – April 2014
PDF is attached to the bottom of this page
Presented at the Bermeyer Coonference in Garmishpartenkirchen (Germany) in March 2012
Text was roughly extracted below for ease of viewing and translation
Scandinavian Journal of Clinical & Laboratory Investigation, 2012; 72(Suppl 243): 129-135
JEAN-CLAUDE SOUBERBIELLE 1 , MARIE COURBEBAISSE2, CATHERINE CORMIER3 , CHARLES PIERROT-DESEILLIGNY4, JEAN-PAUL VIARD5, GUILLAUME JEAN6 & ETIENNE CAVALIER7
1 Service des Explorations Fonctionnelles Hopital Necker-Enfants malades, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, France,
2 Service des Explorations Fonctionnelles, Hopital Europeen Georges Pompidou, Paris, AP-HP, France,
3 Service de Rhumatologie A, Hopital Cochin, Paris, AP-HP, France, ^Service de Neurologie 1, Hopital Salpetriere, Paris, AP-HP, France,
5 Unite fonctionnelle de Therapeutique en Immuno-infectiologie, Hopital Hotel-Dieu, Paris AP-HP, France,
6 Centre de rein artificial, Tassin la demi-lune, France, and 1 Service de chimie clinique, CHU de Liege, Belgium
Correspondence: Jean-Claude Souberbielle, Service des Explorations Fonctionnelles Hopital Necker-Enfants malades, Assistance Publique-Hopitaux de Paris (AP-HP), 149 rue de Sevres, 15015 Paris, France. E-mail: jean-claude.souberbielle at nck.aphp.fr.
The many recently published data on vitamin D have raised much interest in the medical community. One of the consequences has been a great increase in the prescription of vitamin D concentration measurements in clinical practice. It must be reminded that only the measurement of 25-hydroxyvitamin D (25(OH)D) concentration is indicated to evaluate vitamin D status. Furthermore, since vitamin D insufficiency is so common, since treatment is inexpensive and has a large safety margin, and since we already have much data suggesting that besides its classic effects on bone and mineral metabolism, vitamin D may potentially be helpful for the prevention/management of several diseases, perhaps should it be prescribed to everyone without prior testing? In our opinion, there are however groups of patients in whom estimation of vitamin D status is legitimate and may be recommended. This includes patients in whom a "reasonably" evidence-based target concentration (i.e., based on randomized clinical trials when possible) should be achieved and/or maintained such as patients with rickets/osteomalacia, osteoporosis, chronic kidney disease and kidney transplant recipients, malabsorption, primary hyperparathyroidism, granulomatous disease, and those receiving treatments potentially inducing bone loss. Other patients in whom vitamin D concentration may be measured are those with symptoms compatible with a severe vitamin D deficiency or excess persisting without explanation such as those with diffuse pain, or elderly individuals who fall, or those receiving treatments which modify vitamin D metabolism such as some anti-convulsants. Measurement of Vitamin D concentrations ,3 should also be part of any exploration of calcium/phosphorus metabolism which includes measurement of serum calcium, phosphate and PTH.
A considerable amount of recently published data on the proven or potential effects of vitamin D has raised much interest in the medical community. One of the consequences has been a great increase in the prescription of measurements of vitamin D concentration in serum or plasma. In France, for example, the prescription of measurement of 25-hydroxyvitamin D (25(OH)D) concentration has increased almost threefold between 2008 and 2010. As this measurement is reimbursed by the public health insurance (currently 17.55 Euros in France), it seems obvious to evaluate whether these prescriptions are justified or not. It must be emphasized that definitive recommendations on measureing vitamin D concentration or not in general practice must only be released by official Clinical Society such as the Endocrine Society, and, therefore, the following propositions only reflect our current opinion (which may change with the publication of new data) based on our own analysis of the literature, and our routine clinical practice.
‘’First of all it must be reminded that 25(OH)D concentration is the sole measurement indicated to evaluate the individual's vitamin D status’’
This is a consensus, even among groups that have released divergent recommendations on vitamin D [1,2]. The measurement of 1,25-dihydroxyvitamin D (1,25OH2D) concentration, the most active vitamin D metabolite, must be limited to the diagnosis and management of rare disorders of phosphate and vitamin D metabolism, to the management of some patients with renal failure, and to the differential diagnosis of conditions presenting with hypercalcemia/hypercalciuria associated to low/low normal PTH levels.
What is not consensual however is the 25(OH)D cut-off concentration below which vitamin D status may be considered as insufficient. For many vitamin D scientists, including the authors of the present article, the minimum 25(OH)D concentration should be 75 nmol/L [1,3-11], while the recent report by the IOM  indicated that a concentration of 50 nmol/L is largely sufficient and "covers the requirements of at least 97.5 % of the population". Anyway, even with the more conservative IOM cut-off of 50 nmol/L, insufficient vitamin D status is highly frequent. Indeed, approximately 50 % of the general European population has a 25(OH)D concentration below 50 nmol/L, and some groups of patients/subjects such as institutionalized persons, dark-skinned individuals or immigrants, are even very frequently severely deficient (25(OH)D concentration < 25 nmol/L) as reviewed recently .
Administration of vitamin D as a dietary supplement may be considered without prior testing. The reasons may be summarized as low toxicity (even IOM considers up to 4,000 IU/day safe ), deficiency common in the general population and data suggesting benefits in prevention/management of several diseases e.g. colorectal cancer, some infectious diseases, cardiovascular diseases, and some auto-immune diseases. It is not up to us to give advice to the general population, but rather to the health authorities; if they become convinced that a prudent supplementation policy at national or regional level may give a favourable benefit-risk/cost ratio it is their prerogative. The objective would be to increase the 25(OH)D concentration to 50 nmol/L or more for most individuals (95 %?). As a consequence the mean 25(OH)D concentration of the population of most European countries would move from about 50 nmol/L to about 75 nmol/L. An intake of 600 IU/day, as proposed by the IOM group for adults up to 70 years would probably be insufficient, since according to a rule of thumb, 100 IU vitamin D will increase the 25(OH)D serum concentration by a mean 2 to 2.5 nmol/L, with a huge inter-individual variability . Intake of 1,000 IU/day is probably a better choice as suggested by a recent systematic review and meta-regression analysis of the vitamin D intake-serum 25(OH)D relationship .
In the present paper we give our current opinion on which patients need vitamin D testing. Our message is to clinicians who, by definition, see patients, and to clinical chemists who may discuss with the clinicians about the relevance of measuring the 25(OH)D concentration in a given patient. We will separate the patients into two categories.
Patients in whom a "reasonably" evidence-based target concentration should be achieved and/or maintained
First, we must acknowledge that, although plentiful, the many evidences concerning the various potential extra-skeletal effects of vitamin D are mostly based on observational and mechanistic studies. Indeed, numerous prospective studies have shown that subjects in the highest quantile of 25(OH)D concentrations (usually > 70-80 nmol/L) have a lower relative risk for many diseases than those in the lowest quantile (usually < 30—40 nmol/L) [see for example 15-18]. However, the observational nature of these studies does not allow establishing a causal relationship between low vitamin D status and these diseases, and thus prevents defining clear clinical cut-off(s) to optimize these potential effects. We must mention a quite recent article co-signed by some of us (JCS, C P-D, GJ, EC) , which reported the opinion of a panel of 25 experts from various disciplines. In this paper, most authors recommended to measure the 25(OH) D serum concentration in general practice in a myriad of medical conditions including pregnant women, patients with cancers, auto-immune diseases, cardiovascular diseases, hypertension, diabetes. Two years after the submission of this article, we would not give the same advice concerning the need to test vitamin D in these patients. It must be remembered that most studies on which the reasoning of this article was based were published quite recently (2005 and after, see [15-18]), and that many clinicians started to measure 25(OH)D concentrations in their patients at this period and were discovering that vitamin D deficiency/insufficiency (even when defined by a 25(OH)D < 50 nmol/L) is extremely frequent. Furthermore, while it became obvious for these colleagues that vitamin D had to be prescribed to most patients, the recommendations made by experts at this period [19-23] to prescribe higher (often 10 times higher) doses than the current DRI were questioned by many. Indeed, what most doctors had learnt about vitamin D was that it prevents rickets on the one hand, and that it may be toxic on the other hand. They thus expressed the need to understand how the 25(OH)D serum concentration (as well as serum and urinary calcium concentrations) increases when they prescribe vitamin D at doses (much) higher than the DRI. Consequently, they requested an increased number of 25(OH)D concentration measurements. It has become clear that vitamin D intakes of 2,000 IU/day (and even more) are perfectly safe even if administered to subjects who have a spontaneous 25(OH)D concentration in the highest quartile of the general population (usually in the 70-90 nmol/L interval), assuming they have no granulomatous disease (sarcoidosis, tuberculosis...) or hyper-sensitivity to vitamin D due to a genetic defect . We thus do not recommend a systematic evaluation of the vitamin D status any more in patients with (or at risk of) cardiovascular diseases, auto-immune diseases, cancers, infections, or in pregnant or lactating women. As indicated in the introduction, this opinion may change again according to newly published data (for example if one of the ongoing RCTs demonstrates that vitamin D supplementation improves one or several clinical outcomes if a given 25(OH)D concentration is achieved). In the interval, we propose to supplement these patients with vitamin D without prior testing (although we don 't consider that measuring 25(OH)D concentration in some cancer, multiple sclerosis, HIV, or hypertensive patients is a "crime"). We acknowledge however that providing this kind of recommendations or suggestions that is based on published data and experience, and the situation of the physician who has to decide to measure or not to measure 25(OH) D concentration in a given patient, are two very different things. We are aware that in our countries (France and Belgium) at least, many doctors are still reluctant to prescribe vitamin D supplementation without knowing the vitamin D status of their patients. Similarly, some patients would not agree to take a vitamin D treatment if a vitamin D deficiency/insufficiency has not been evidenced by a low 25(OH)D concentration. For those doctors who will agree with our suggestion, the doses suggested by the Endocrine Society group as being the mean daily requirement are encouraged (for example 1,500-2,000 IU/day for adults - see Table III in ). It is probable that, with these doses, and due to an important inter-individual variability in the 25(OH)D response to a given vitamin D dose, not everybody will have a 25(OH)D concentration above 75 nmol/L, whereas a concentration of more than 50 nmol/L can be expected in most patients.
In our opinion, there are however groups of patients in whom measurements of vitamin D concentration are highly legitimate. The Endocrine Society group  proposes, and we fully agree, that vitamin D deficiency corresponds to 25(OH)D concentrations < 50 nmol/L, and insufficiency to concentrations of 50 to 75 nmol/L. In clinical practice, we want that our patients achieve a "sufficient" level; our target concentration is thus above 75 nmol/L. Like the Endocrine Society group, we acknowledge that this cut-off concentration is only "reasonably evidence-based" for the musculoskeletal health and mineral metabolism (prevention of rickets/osteomalacia, elevated PTH levels, osteoporotic fractures and falls in the elderly). Indeed, in the RCTs that shown positive effects of vitamin D on non-vertebral fractures  and falls , of subjects in the "vitamin D groups" had generally 25(OH)D concentrations of more than 75 nmol/L, whereas those in the "placebo groups" had concentrations in the 30-60 nmol/L interval. Consistent with these, bone biopsy data showed that histomorphometric signs of osteomalacia are not detected in subjects with a serum 25(OH) D concentration of more than 75 nmol/L whereas they are present, as defined by the most conservative threshold of the OV/BV ratio of 2 %, in approximately 10 % of those with a 25(OH)D concentration between 50 and 75 nmol/L . Furthermore, Japanese patients with a basal 25(OH)D concentration of up to 70 nmol/L decreased their PTH concentration when they were given vitamin D (without calcium) , while the relationship between serum 25(OH)D and PTH concentrations in various populations indicated in some studies that the PTH concentration may increase when 25(OH)D is below 75-80 nmol/L. Due to uncertainty in 25(OH) D measurements (comparable to that of the measurement of other steroid hormones), a best estimate of 75 nmol/L allows for a uncertainty interval between 60 and 90 nmol/L . Among patients in whom we propose to measure 25(OH)D, we include:
- Patients with rickets/osteomalacia.
- Patients with osteoporosis (with and without fracture). In these patients we recommend measuring 25(OH)D at diagnosis, as a part of a more extensive evaluation of possible secondary causes of low bone mass (including at least concentrations of serum calcium, phosphate, PTH, protein electrophoresis, blood cell count, CRP) . If the 25(OH)D concentration is < 75 nmol/L it is proposed to prescribe vitamin D according to a "correction" protocol (examples to be found in [2,10,11,19]). After this first stage (aiming at increasing the 25(OH)D concentration to a value > 75 nmol/L) a "maintaining" treatment (aiming at maintaining the 25(OH)D concentration above 75 nmol/L) must be initiated (for example 1,500 2,000 IU/day or its equivalent given in weekly, monthly, or bi-monthly doses). We recommend to monitor the 25(OH)D concentration during this "maintaining" treatment (measure 25(OH) D after 4-6 months in case of daily treatment, and, in case of intermittent treatment, after 6 months of treatment, just before a dose is given) and adapt the posology according to the measured value.
- Patients at risk of osteoporosis/bone loss because they receive specific treatments such as gluco-corticoids chronically at a dose of 7 mg prednisone or more for any cause (see a recent review in ), analogs of GnRH for prostate cancer, or anti-aromatase therapy for breast cancer . In these patients, 25(OH)D measurement may be done 4-6 months after a vitamin D treatment (1,500-2,000IU/day) is initiated to adapt the posology.
- Patients at risk of osteoporosis/bone loss because they have a malabsorption syndrome (celiac disease, inflammatory bowel disease, cystic fibrosis, Crohn's disease...) in whom higher vitamin D doses are generally required. Similarly, 25(OH)D concentration measurement may be done 4-6 months after a vitamin D treatment (3,000-4,000 IU/day) is initiated to adapt the posology.
- Patient who had bariatric Surgery, specially gastric bypass. Obese patients are usually vitamin D deficient but are not osteoporotic. However, after gastric bypass they have an accelerated bone loss. These patients cumulate two reasons for being vitamin D deficient: 1) even if they have lost 50 kg or more, they are usually still obese and store vitamin D in their fat mass, and 2) they have a malabsorption due to the surgical procedure. They usually need much higher vitamin D doses than the other patients .
- Patients with chronic kidney disease (CKD) stage 3-5D and kidney transplant recipients. Measuring 25(OH)D concentrations in CKD patients and treating vitamin D deficiency/ insufficiency as in the general population is a recommendation of the KDIGO guidelines . This recommendation is in fact only a suggestion which is graded 2C. Secondary hyperparathyroidism is a hallmark of CKD, with several deleterious consequences. It must be underlined that until recently, nephrolo-gists used to treat their patients with active vitamin D (analogs of calcitriol), not "mother" vitamin D, to control PTH secretion. Recent studies have shown that supplementation with cholecalciferol or ergocalciferol was able to decrease modestly but significantly PTH concentrations not only in non-dialyzed, but also in dialyzed and in transplant patients [34-37]. Furthermore, several prospective observational and non randomized interven-tional studies have linked vitamin D deficiency to increased mortality in CKD , accelerated GFR loss , and albuminuria . Consequently supplementation with vitamin D is an increasing practice in CKD patients. We have shown that monthly supplementation with 100,000 IU vitamin D3 decreases PTH and is adequate to maintain the 25(OH)D concentration of most dialyzed  and kidney transplant patients  above 75 nmol/L, whereas 100,000 IU every two months failed to maintain this concentration in approximately one half of our kidney transplant recipients .
- Patients with primary hyperparathyroidism (PHPT). These patients are often vitamin D deficient and osteoporotic, but they are also hypercalcemic. Treating hypercalcemic patients with a molecule that increases calcium absorption, and which may, when given at extremely large doses, cause hypercalcemia, hypercalciuria, and extra-skeletal calcifications was regarded with suspicion by most physicians. It was shown in 2005 that the administration of large doses of cholecalciferol to PHPT patients with a serum calcium concentration < 3 mmol/L did not increase serum calcium or phosphate, and decreased PTH significantly . This was followed by similar published results (reviewed in ) so that the expert panel for the diagnosis/ management of asymptomatic PHPT recommended to treat any PHPT patient with a 25(OH)D concentration < 50 nmol/L with vitamin D. It is also recommended to supplement all PHPT patients with vitamin D (and calcium) once they have been surgically treated. This will allow an increase in bone mineral density and prevent symptomatic hypocalcemia due to "hungry bone syndrome" . In our experience, 25(OH)D concentrations > 75 nmol/L (and sometimes more) are to be targeted after parathyroidectomy.
- Patients with granulomatous disorders such as sarcoidosis or tuberculosis. In these patients it is prudent to target a 25(OH)D concentration around 50 nmol/L to avoid both hypercalcemia/hypercalciuria due to uncontrolled synthesis of calcitriol on the one side, and severe vitamin D deficiency, which is frequent in these patients because of the fear of inducing hypercalcemia, on the other side. For the patients of the above category, adherence/observance to vitamin D supplementation will be a concern. It is thus not unrealistic to measure 25(OH)D at intervals in these patients. It is logical to measure 25(OH)D at its theoretical nadir, i.e. during the winter months if possible, and just before a dose is taken in case of intermittent dosage administered at intervals of one month or more.
- Patients in whom a severe vitamin D deficiency or excess should be excluded without a special 25(OH)D concentration interval to be targeted. This includes patients in whom symptoms compatible with a severe vitamin deficiency (such as those with diffuse pain or elderly subjects who frequently fall), or with a vitamin D intoxication (such as those with extra-skeletal calcifications, nephrocalcinosis or recurrent renal stones) are present and persist without a clear explanation. Patients having a disease, such as hepatic failure, or receiving treatments that may modify vitamin D metabolism such as some anti-convulsants or ketokonazole can be included in this category. In these patients there is no special 25(OH)D concentration interval recommended although it is logical to consider 50-150 nmol/L as this would be unlikely be associated with these symptoms.
More generally, measurement of 25(OH)D concentration is recommended in any patients in whom an exploration of calcium/phosphate metabolism which includes a measurement of serum PTH is prescribed. Besides osteoporotic patients in whom the aim is to exclude a secondary cause of low bone mass and/or fractures, it should be prescribed in patients with renal lithiasis, chondrocalcinosis, and in case of persistence (without explanation) of symptoms of both hyper- or hypocalcemia. In such cases it is especially important to know the 25(OH) D concentration when a high PTH concentration is detected in patients with otherwise normal serum calcium and phosphate concentrations. The 25(OH) D concentration may help differentiating between a secondary hyperparathyroidism, and a so-called "normocalcemic" PHPT. This is now recognized as a separate and quite frequent entity, which probably necessitates the same treatment as hypercalcemic PHPT when osteoporosis, renal lithiasis or renal failure is present .
Growing interest for vitamin D and its proven or potential effects has induced a dramatic increase in the prescription of measuring vitamin D concentration in clinical practice. Although we consider that in many patients, these prescriptions are not justified, and that these patients should receive vitamin D without prior testing according to recent recommendations , still continue to consider that estimating vitamin D status by measuring the 25(OH)D concentration is largely legitimate in several groups of patientsWe insist on the fact that this article reflects our current opinion which may change depending on the publication of the results of several ongoing clinical trials.
You mentioned that you have a very heavy reimbursement in France for 25(OH)D measurements. I would like to take issue with one of your points. You said that with glucocorticoid treatment, you need to measure 25(OH)D. I would advocate that in view of the deleterious effect of glucocorticoids on bone, we shouldn't wait for measurement and supplement immediately. What do you think?
You are correct. Of course you should give vitamin D without testing in patients on glucocorticoids for whatever reason but after a few months of treatment you should measure vitamin D to ensure you are achieving concentrations in the required interval. It is different in patients with osteoporosis. Then you must know the 25(OH)D concentration at the beginning.
You showed the enormous increase in the number of serum 25(OH)D measurements in France. I suspect the same is true in all our countries and it is not caused by the patients in whom you have advocated measurement. It is caused in my experience largely by the popular press and the media which are persuading people to have their vitamin D status checked because of its importance in protecting against a variety of conditions. It is a huge issue, often being driven by relatively weak science. People are demanding measurement of 25(OH)D concentrations through primary care physicians when they have a variety of non-specific symptoms. Is that primary care physician ever going to say 'No'?
I think it is for the Health Authority to give recommendations. It is difficult; we give recommendations based on the literature, but when you are in your office with a patient, that is very different!
The authors alone are responsible for the content and writing of the paper.
 Holick M, Binkley N, Bischoff-Ferrari H,Gordon C, Hanley D, et al. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930.
 Ross C, Manson JE, Abrams S, Aloia J, Brannon P, Clinton S, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.
 Norman A. Vitamin D nutrition is at a crossroads. Public Health Nutrition 2011;14:750-751.
 Adams J, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010;95:471-478.
 Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckardt P, Fuleihan GEH, et al. IOF position statements: vitamin D recommendations for older adults. Osteoporos Int 2010;21:1151-1154.
 Perez-Lopez F, Brincat M, Erel T, Erel T, Tremollieres F,
Gambacciani M, et al. EMAS position statement: vitamin D and postmenopausal health. Maturitas 2012;71:194-198.
 Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 2004;89: 575-579.
 Bischoff-Ferrari H, Giovanucci E, Willett W, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple outcomes. Am J Clin Nutr 2006;84:18-28.
 Dawson-Hughes B, Heaney R, Holick M, Lips P, Meunier P, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716.
 Hanley D, Cranney A, Jones G, Whiting S, Leslie W,Cole D, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182:E610-E618.
 Souberbielle JC, Body JJ, Lappe J, Plebani M, Schoenfeld Y, Wang T, et al. Vitamin D and musculoskeletal health, car-  diovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmunity Reviews 2010; 9:709-715.
 Mithal A,Wahl DA, Bonjour JP, Burckardt P, Dawson-Hughes B, Eisman J, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;11:1807-1820.
 Heaney RP. Vitamin D in health and disease. Clin J Am Soc  Nephrol 2008;3:1535-1541.
 Cashman K, Fitzgerald A, Kiely M, Seamans K. A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br J Nutr 2011;106: 1617-1627.
 Leu M, Giovannucci E. Vitamin D: epidemiology of cardiovascular risks and events. Best Practice & Research Clinical Endocrinology & Metabolism 2011;25:633-646.
 Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29:3775-3782.
 Munger K, Levin L, Hollis B, Howard N, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.JAMA 2006;296:2832-2838.
 Bodnar L, Catov J, Simhan H, Holick M, Powers R, Roberts J. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007;92:3517-3522.
 Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-81.
 Bischoff-Ferrari H. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 2007;18: 401-407.
 Vieth R, Bischoff-Ferrari H, Boucher B, Dawson-Hughes B, Garland C, Heaney R, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-650.
 Heaney R, Davies M, Chen TC, Holick M, Barger-Lux J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-210.
 Yendt E, Kovacs K, Jones G. Secondary hyperparathyroid-ism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction. Clinical Endocrinology 2008;69:855-863.
Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011;365:410-421. Bischoff-Ferrari H, Willett W, Wong J, Stuck A, Staehelin H, Orav J, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch Int Med 2009;169: 551-561.
Bischoff-Ferrari H, Dawson-Hughes B, Staehelin HB, Orav J, Stuck A, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009;339:b3692. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010;25:305-312.
Okazaki R, Sugimoto T, Kaji H, Fujii Y, Shiraki M, Inoue D, et al. Vitamin D insufficiency defined by serum 25-hy-droxyvitamin D and parathyroid hormone before and after oral vitamin D3 supplementation load in Japanese patients. J Bone Miner Metab 2011;29:103-110. Cavalier E, Rozet E, Gadisseur R, Carlisi A, Monge M, Chapelle JP, et al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut-offs. Osteoporos Int 2010;21:1047-1051. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 2008;19:991-999. Davidson Z, Walker K, Truby H. Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab 2012;97 (in press).
Camacho P, Dayal A, Diaz J, Nabhan F, Agarwal M, Norton J, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008;26:5380-5385.
KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 79:S1-S130.
Kandula P, Dobre M, Schold JD, Schreiber M, Mehrotra R, Navaneethan S. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am
Soc Nephrol 2011;6:50-62.
Jean G, Souberbielle JC, Chazot C. Strategy for vitamin D supplementation. Monthly cholecalciferol administration in hemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009;24:
Matias PJ, Jorge C, Ferreira C, Borges C, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimensions parameters. Clin J Am Soc Nephrol 2010;5:905-911.
Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009;75:646-651. Pilz S, Iodice S, Zittermann A, Grant W, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011;58: 374-382.
de Boer IH, Katz R, Chonchol M, Sarnak M, Shlipak M, Siskovick D, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 2011;6:2141-2149.
Kim MJ, Frankel A, Donaldson M, Darch S, Pusey C, Hill
P, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-P1 in patients with type 2 diabetic nephropathy on established renin-angiotensin -aldosterone system inhibition. Kidney Int 2011;80:851-860.
 Grey A, Lucas J, Horne A, Gamble G, Davidson J, Reid I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005;90:2122-2126.
 Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol 2010;121:199-203.
 Eastell R, Arnold A, Brandi ML, Brown E, D ' Amour P, Hanley D, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94: 340-350.
 Lowe H, McMahon DJ, Rubin M, Bilezikian J, Silverberg S. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001-3005.